Lipid-lowering therapy
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
... recommends an algorithm which takes into account a range of factors when deciding on the need for lipid- lowering therapy. These include age, race, smoking pres- ence of CVD or history of major ...
9
Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
... of therapy non-HDL-C would also have to predict cardiovascular events in patients on ...of lipid-lowering trials is strongly ...of therapy would probably mean intensifi cation of lipid ...
14
Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology
... Methods: We analyzed data from 61 patients with stable angina pectoris included to the PREDICT trial searching for prediction of plaque changes during intensive lipid-lowering therapy (40 mg ...
15
<p>Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany</p>
... with lipid-lowering therapy (LLT) such as statins, cholesterol absorption inhibitors, or PCSK9 inhibitors is of major importance for the survival of patients with atherosclerotic diseases, and ...
7
Statins: Newer Roles Including Lipid Lowering Therapy
... addition, lipid- lowering therapy was associated with significant reduction in both cardiac mortality and all-cause death in larger cohort of patients treated with antiarrhythmic drug ...statin ...
10
Lipid-lowering therapy: who can benefit
... intensive lipid-lowering therapy observed in trials with clinical end points and suggest that the aggressive LDL-C goal of , 70 mg/dL may be beneficial for specific patient groups, such as high- risk ...
10
The role of soluble fiber intake in patients under highly effective lipid-lowering therapy
... for lipid-lowering therapy in accordance with the National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP III) guide- lines ...the lipid-lowering regimen or to the daily ...
8
Prevalence, factors influencing and knowledge about adherence to lipid lowering therapy among hyperlipidemia patients
... includes therapy related reasons (6 items), health-care team and system related reasons (4 items), socio-economic reasons (3 items) and patient’s related reasons (3 items) while chronic conditions related reasons ...
8
<p>Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings</p>
... statin therapy at the suitable intensity with no potential safety issues with co- administered ...statin therapy despite having no contraindications or those who received non-statin therapy without ...
9
Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy
... complete lipid profile was assayed by standard techniques in 12-h fast- ing blood samples, including TC, HDL, LDL, triglycer- ides, apoA and apoB and Lp(a) ...
7
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
... with lipid lowering drugs, including a large percentage of patients with hypertension, were collected from 122 hospitals in 6 geographic regions of China between April 2012 and October ...accepted ...
11
CARDIOPROTECTION WITH SIMVASTATIN: AN APPRAISAL
... a lipid lowering therapy in patients with CHD 24 ...drug therapy with excellent tolerability that shows persistent lipid-lowering effect during long-term treatment of ...
5
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy
... event lowering in diabetes (FIELD) study found that fenofibrate reduced the progression of DR in patients with type 2 diabetes [16, ...simvastatin therapy slowed the progression of DR in patients with type ...
7
The Impact of Statin Intolerance in Lipid Clinic Patients
... their lipid-lowering therapy, it is essential to reduce their cardiovascular ...“moderated” therapy with combination of low intensity statin and another lipid modifying medications ...
8
Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy
... during lipid-lowering therapy in patients with familial hypercholesterolemia (FH), which usually re- quires the coadministration of different types of such drugs ...different ...
6
Adherence to lipid-lowering treatment: the patient perspective
... effective lipid-lowering medications, such as the HMG-CoA reductase inhibitors (statins), a large portion of the population has lipid levels higher than the recommended ...to therapy in the ...
10
<p>Impact of Pharmacist-Led Interventions on Medication Adherence and Clinical Outcomes in Patients with Hypertension and Hyperlipidemia: A Scoping Review of Published Literature</p>
... and lipid-lowering therapy were less likely to have a signi fi cant impact on the clinical outcomes despite their signi fi cant impact on medicine ...
11
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
... with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol ...
11
Transitioning from population to individualized preventive cardiology
... of lipid-lowering therapy to established low-density lipoprotein cholesterol (LDL-C) goals, significant residual risk for cardiovascular events remains in patients with established cardiovascular ...
5
Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
... We analysed data from two lomitapide studies: a single-arm, open label, Phase 3 clinical trial of lomitapide in adult patients with HoFH (NCT00730236; the ‘pivotal trial’) and its single-arm extension study (NCT00943306; ...
6